03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate of...
19:04 , Mar 23, 2018 |  BC Week In Review  |  Financial News

GlycoMimetics reaps $119M in bumped-up follow-on

GlycoMimetics Inc. (NASDAQ:GLYC) raised $119 million on March 20 through the sale of 7 million shares at $17 in an upsized follow-on underwritten by Jefferies, Cowen, Stifel, SunTrust Robinson Humphrey and Roth Capital Partners. The...
17:08 , Mar 21, 2018 |  BC Extra  |  Financial News

GlycoMimetics reaps $119M in bumped-up follow-on

GlycoMimetics Inc. (NASDAQ:GLYC) raised $119 million through the sale of 7 million shares at $17 in an upsized follow-on underwritten by Jefferies, Cowen, Stifel, SunTrust Robinson Humphrey and Roth Capital Partners. The price is a...
00:00 , Mar 7, 2018 |  BC Extra  |  Clinical News

GlycoMimetics falls on Phase III AML trial design

GlycoMimetics Inc. (NASDAQ:GLYC) lost $4.07 (18%) to $18.75 on Tuesday after the company unveiled late Monday the design of its Phase III trial for acute myelogenous leukemia candidate GMI-1271. The primary endpoint of the trial,...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
02:15 , Dec 16, 2017 |  BioCentury  |  Product Development

Assessing the BCMA scene

Differences in patient populations and a dearth of clinical outcome data mean it’s too soon to declare bluebird bio Inc.’s anti-BCMA chimeric antigen receptor therapy the leader of the pack of CARs that presented clinical...
17:02 , Dec 15, 2017 |  BC Week In Review  |  Clinical News

GlycoMimetics reports updated Phase I/II AML data for GMI-1271

GlycoMimetics (NASDAQ:GLYC) reported updated data at the American Society of Hematology meeting from a Phase I/II trial of GMI-1271 to treat acute myelogenous leukemia (AML). The company plans to start a Phase III trial in...
21:58 , Dec 12, 2017 |  BC Extra  |  Clinical News

GlycoMimetics gains on updated AML data at ASH

GlycoMimetics jumped $2.13 (15%) to $16.45 on Tuesday after reporting updated data at the American Society of Hematology meeting from a Phase I/II trial of GMI-1271 to treat acute myelogenous leukemia. The company plans to...
22:43 , Jul 7, 2017 |  BioCentury  |  Finance

Generalists needed

Following a nearly two-year political overhang on the biotech sector, buysiders believe sentiment once again may be turning positive and starting to catch up with the industry’s positive fundamentals. As evidence, they point to the continued...
18:34 , Jun 9, 2017 |  BioCentury  |  Regulation

New SOC in sickle cell?

If FDA follows ODAC’s recommendation to approve Endari L-glutamine from Emmaus Life Sciences Inc., the candidate is likely to become the backbone of sickle cell therapy. On May 24, FDA’s Oncologic Drugs Advisory Committee voted...